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WmberS of Pts from each region and (heir characteristics are Shown m the 
table. Although selection brases affect the ‘ypes of PCs entered tn a clinical 
trial, these data Indicate that while the enro d SMF Pts are simils in many ot 
these regions. several potenlially important diIferencffS exist (etiology of CHF, 
prevalence of hypenens!on and diabetes. use of CABG). Such differences 
may impact on results applicablllty of trials conducted In single countries or 
regions. 
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Congestive heart failure (CMF) is charactmized by a high morbidity and 
modality. Although a large number 01 drugs am cunenIIy used in CHF, the 
use of these various agents is not unifon. In order IO examine treatment 
palterns for CHF between countries. we examined drug use m patients (pts~ 
who were part of the PRIME-II Trial (lbopamine Survival Study). A total of 
1806 NYHA ctass lit-IVpts were randomized from 199210 1996. AlIhough 13 
European countries participated, we only examined countries who included 
GO pts. leaving a study population of 1625 pts from 9 countries. At baseline. 
pls had an ACE-inhibitor (unless intolerant = 8%) and diurekcs. (data are 
% pts on class of drugJ.(NL = Netherlands, UK = llnited Kingdom. GER = 
Germany. IT = Italy. FR = France, BE.Belgium, SP = Spain. SW 5 SwiIzeriand. 
OK = Denmark). 
NL UK GER IT m BE SP SW OK 
no. pts 427 337 223 220 208 124 123 62 61 
dtgllalls 60 39 67 81 56 62 71 65 77 
lull-dose ACEmh’ 25 35 16 19 22 17 32 29 25 
an%anhythmcs 16 23 19 25 44 26 16 32 15 
bet+blockers 11 2 10 3 3 10 3 6 7 
ca.bloCkerg 7 t* 13 5 15 2 5 1 9 
anllcoagulanls 70 39 42 2: 19 23 47 66 31 
an\lplaWtels 18 43 32 24 26 32 31 23 5.1 
t 3 . 50 mg edptopnl. 2 . 20 mg enalapnl or eqwaxn. 2 * 90% ammdarone 
C0ncrusion.s: large differences in drug use for patients with moderate 
to severe CHF are observed between (European) countries. Whether this 
is related IO factors such as tradition. economic/financial circumstances. 
national guidelines. etc. is unknown. but this issue needs further study. 
[ 1044-31 1 Reduced HospitalizMions and Health Care Casts 
by an Interactive Home Monitoring Program for 
Heart Failure Patients 
P.A. Heidenreich, C. Ruggerio. B.M. Massie. Star&u’ University Sian&d, 
CA and University of Califomfa. San Francisco, CA, USA 
Chronic heart failure is associated with frequent hospitalizations and high 
resource use. This study examined the effect of a multidimensional program 
of patient (pt.) educalion. monitoring, and physician nolification on medical 
costs and hospilali:atons. 68 ptS. of a community-based medical group with 
heart failure. (NYHA class Z-4) were enrolled. Each patient (me- age 73 * 
5 yrs., 59% male) received an electronic BP cuff. digital scale, and weekly 
educational mailings. Palients were contacted weekly by a nurse to evaluate 
clinical status. Vital signs, weight. and Symptoms were recorded dally using 
a computerized phone system. Physicians were notified by fax of abnormal 
Vital Signs, SymptOmS, or weight Changes. During ‘12 f- 5 mos. Of tOtlOW-Up 
284 MD notifications occurred for 53 pts.; 42% of notifications were followed 
by an intervention (medication change 39% or clinic visit 24%) Within 14 
days. Program patients with claims data from 1995 (N = 43) were matched 
(based on gender, age, and 1996 claims) to 66 heart failure pafienls who 
were not enrolled. Medical claims, log (claims), admissions. and hospital 
days in 1996 were reduced for patients in the program (Table). The program 
was rated good or excellent by 97% 01 pts. In summary. this sway s~ggost~ 
that a mUlIiUimenSiOna1 monilonng program for pallents with hearc la&lure ten 
reduce hospltalizatlons and medical costs. 
Group N 
Program 43 
Contra1 86 
’ F .I 0.05 
iIzl 1044 32 Shurt-term Outcomea and In-ttospltaf ~erource UWatlon In Heart Fnllure: A Comparison of 
Syfftollc Verwr Olaatollc Dyafunctlon 
K.J. HarM. T. Tutgut. M. Shah, JS. tiumphde, J. Newman, J. Cheint. 
H. Ventura, F. Smelt. Ochsner M&Scat IrWluflons, New Orleans. Louisiana, 
USA 
Background: The #feel 01 loft ventricular ejsctlon Irccctlon (LvEF) on short. 
term clinical outcomes and resource utilixatlon during hospitalization for head 
failure has not bean evaluated. 
Melhods: In d43 consecutive hospitalizations for heart failure tn patients 
with known LVEF, we compared mhospltal and 30&y mor18111y, 30+ 
readmisslon rates, hospltallzatlon cost. and length of stay between patients 
with systolic dysfunction (LVEF 5 40%; Group I: n = 266) versus those with 
diastolic dysfunction (LVEF > 40%; Group II: n I 157). 
ReSuRS: Patients with Systolic dySfuncIion were younger (69 vs 73 yean: 
p = O.OOl), less likely to be white (59% vs 73%. p s 0.007). and tended to 
be male mure often (68% vs 49%: p = 0.08) compared IO tie wiIh diastolic 
dysfunction. They were less likely IO have atria1 fibrillation (309’. vs 44%; p z 
0.002). but equally likely lo have hypertension and coronary artery disease. 
Shart.term oulcomes and resource ullllzatlon. expressed per hospitalization. 
are shawn below: 
Length of stay (day9 4.0 37 003 
Wosplsl!zatlan co$ts f US S) 3.016 2.825 0.06 
In-hospitatmmtality 2 596 2.6% NS 
3OdaY moIlaMY 4.0% 4 6% NS 
-“May readmrsstons (any cause) 0.39 025 005 
3Oday readmwons (heart tatlure) 022 0 11 0.01 
Munmle readmlssvxt6v 6.lZ 2 1% 001 
c~nC~u,Yiorts; Followmg hospilalrzation tor heari fa!lure. parents wrth mod. 
emI@ or severe left ventncular dysfunc!Km have greater resource ut!llratlon 
and readmissions. buI similar short-term monakty compared IO patlen& wl!h 
mild or no systolic dystunction. 
1-I 1044 33 Gender Biab in the Medical Management of Heart Failure: The Cardiologist Versus the 
Non-Cardiologist 
K.J. Haiai, E. Nunez. J.S. Humphne. T. furgut. J. Newman. Ochsner 
Me&el Instibrriuns. New Orleans. Louisiana. USA 
Backgtuund; The purpose of this study was to assess if gender bias exists in 
the r.lanagement of heart failure (HF). and to evaluate its relation to ceregiver 
specialty (cardldogist vs non-cardiologist). 
Methods: In 309 consecutive hospitalizations for HF in 216 pts (66 f 14 
yrs: 61% male) with LV ejection fraction _ ~453’0. we examined the relation of 
pt gender with uliiization of lhe followIn<; medications at lhe time of hospdai 
discharge: vasodilalors. diuretics, cligoxin. and combined therapy (COMB, 
i.e. vasodilator + diuretic + cligoxin). Using clinical data, we devetoped mul, 
tiple logistic regr@$sion models to predict the likekhood that pts would be 
discharged from the hospital on treatment with these medications. pt gender 
and caregiver speciaky were forced into the models. 
ResulIs: The Irequencies of use cf vasodilators. diuretics. UIgoxin. and 
COMB at Ihe time of &charge were 66. 92. 77. and 66% respectively. PI 
gender was not assoctated wilh use 0. _ 1 POME in univariate or multtvariate 
analyses. However, the interaction term ot gender and CaregIver specialty 
was stgnificantly associated with COMB (p = 0.01). Thus. cardtologi~s were 
more likely to employ COMB in males vs females (adjusted probability 73 yi; 
59%). while non-cdrdiologish util:;tedCOMB less often in males (46 Vs 7696). 
Similarly. cardiologists used digoxin more often in males (60 vs 73%). while 
non-cardiologists used it more often in femafes (55 vs 9@‘6). NO eSSociaIron 
was seen beIween gender and use of vasodilators or dlureticS. When Only 
the RrSt hospitalizations of each pt were ?nalyZed, gender a,nd caregiver 
specialty ahowed similar asS@ciat~ons with use of COME and dlgoxin. 
Conclusions: 1) pl;,snXicant differences exist cn the utd~zation of effective 
nwdiwtions in male vs fe.mafe 016 with HF: these findmgs raise the possibility 
